

Table S1 Patient and clinical characteristics of patients hospitalized for COVID-19 divided by the number of symptoms clusters affected.

Patient characteristic	0 cluster (n=12)	1 cluster (n=28)	2 clusters (n=55)	3 clusters (n=74)	4 clusters (n=218)
Age, years	65.4 ± 11.8	63.0 ± 10.7	58.7 ± 11.6	61.7 ± 11.9	59.5 ± 9.8
Sex, male	12 (100.0)	23 (82.1)	44 (80.0)	54 (73.0)	141 (64.7)
BMI, kg/m ²	26.6 ± 4.0	27.7 ± 4.6	29.8 ± 5.4	29.1 ± 5.2	29.9 ± 5.8
<i>Migration Background</i>					
European	11 (91.7)	23 (82.1)	41 (74.5)	56 (75.7)	164 (75.2)
Dutch Caribbean	0 (0.0)	2 (7.1)	10 (18.2)	7 (9.5)	28 (12.8)
Asian	0 (0.0)	1 (3.6)	1 (1.8)	9 (12.2)	11 (5.0)
Turkish	0 (0.0)	0 (0.0)	3 (5.5)	2 (2.7)	8 (3.7)
(North) African	1 (8.3)	2 (7.1)	0 (0.0)	0 (0.0)	7 (3.2)
<i>Pre-COVID education</i>					
Low	4 (33.3)	8 (28.6)	18 (32.7)	29 (39.7)	73 (33.6)
Middle	5 (41.7)	11 (39.3)	18 (32.7)	21 (28.8)	81 (37.3)
High	3 (25.0)	9 (32.1)	19 (34.5)	23 (31.5)	63 (29.0)
<i>Pre-COVID employment</i>					
Unemployed	1 (8.3)	3 (10.7)	12 (21.8)	12 (16.4)	35 (16.1)
Employed	5 (41.7)	17 (60.7)	28 (50.9)	40 (54.8)	146 (67.0)
Retired	6 (50.0)	8 (28.6)	15 (27.3)	21 (28.8)	37 (17.0)
<i>Smoking status</i>					
Never	4 (33.3)	14 (50.0)	24 (43.6)	24 (32.4)	89 (40.8)
Former	8 (66.7)	14 (50.0)	30 (54.5)	50 (67.6)	123 (56.4)
Current	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	6 (2.8)
<i>Comorbidities</i>					
≥1	7 (58.3)	19 (67.9)	45 (81.8)	62 (83.8)	186 (85.3)
Obesity (BMI≥30)	2 (16.7)	7 (25.0)	22 (40.0)	31 (41.9)	84 (38.5)
Diabetes	2 (16.7)	6 (21.4)	12 (21.8)	12 (16.2)	46 (21.1)
Cardiovascular disease/ hypertension	3 (25.0)	10 (35.7)	17 (30.9)	35 (47.3)	88 (40.4)
Pulmonary disease	2 (16.7)	3 (10.7)	13 (23.6)	14 (18.9)	69 (31.7)
Renal disease	0 (100.0)	2 (7.1)	6 (10.9)	11 (14.9)	18 (8.3)
Gastrointestinal disease	0 (100.0)	0 (100.0)	3 (5.5)	3 (4.1)	7 (3.2)

Neuromuscular disease	1 (8.3)	3 (10.7)	5 (9.1)	7 (9.5)	19 (8.7)
Malignancy	1 (8.3)	4 (14.3)	4 (7.3)	16 (21.6)	22 (10.1)
Autoimmune/inflammatory disease	1 (8.3)	4 (14.3)	4 (7.3)	7 (9.5)	27 (12.4)
Mental disorder	0 (100.0)	3 (10.7)	2 (3.6)	3 (4.1)	13 (6.0)
In-hospital characteristics					
PCR confirmed SARS-CoV-2	12 (100.0)	28 (100.0)	55 (100.0)	73 (100.0)	215 (98.6)
Serology confirmed SARS-CoV-2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (1.8)
<i>Laboratory values</i>					
Creatinine, umol/L	75.0 (68.0-88.8)	83.0 (75.0-91.0)	86.0 (75.0-104.8)	84.0 (70.0-107.0)	82.0 (68.3-100.0)
(CKD-EPI) eGFR, ml/min	89.0 (76.3-90.0)	82.5 (71.3-90.0)	84.0 (59.5-90.0)	78.0 (61.0-90.0)	81.5 (66.0-90.0)
CRP, mg/L	143.0 (54.8-160.0)	112.0 (55.0-190.0)	109.0 (50.0-164.0)	81.5 (50.3-148.8)	85.0 (45.0-153.5)
Ferritin, ug/L	870.5 (686.8-1186.3)	1456.5 (411.3-2054.8)	1339.0 (515.3-1900.3)	980.0 (539.3-2410.5)	832.5 (435.5-1447.3)
ALAT, U/L	38.5 (21.8-43.8)	29.0 (20.0-56.0)	39.0 (29.5-53.0)	38.5 (24.8-62.3)	36.0 (26.0-58.0)
Hemoglobin, mmol/L	8.7 (8.3-9.2)	8.8 (8.0-9.8)	9.0 (7.9-9.3)	8.6 (7.7-9.2)	8.6 (8.0-9.2)
MCV, fl	90.0 (88.0-92.0)	88.0 (87.0-92.0)	88.0 (85.0-90.3)	88.0 (84.3-92.0)	88.0 (85.0-91.0)
Trombocytin, 10 ⁹ /L	289.0 (212.0-337.0)	199.5 (158.0-257.3)	218.0 (174.0-269.0)	191.0 (143.0-297.0)	216.0 (160.0-276.5)
Lymphocytes absolute count, 10 ⁹ /L	0.6 (0.5-1.0)	0.8 (0.6-1.2)	0.9 (0.6-1.1)	0.8 (0.5-1.0)	0.9 (0.6-1.1)
D-dimer, mg/L	929.0 (2.9-1522.0)	863.0 (420.0-2802.0)	1.2 (0.7-415.3)	1.0 (0.6-7.9)	1.2 (0.6-509.8)
NT-pro-BNP, pmol/ml	44.0 (18.0-na)	18.0 (5.0-na)	23.0 (7.5-42.0)	35.5 (19.3-77.3)	16.0 (7.0-42.0)
IL-6, pmol/ml	-	-	44.0 (32.0-83.8)	280.0 (52.5-614.5)	34.0 (26.0-191.0)
<i>Chest x-ray abnormalities</i>					
Normal	2 (16.7)	3 (10.7)	6 (11.3)	8 (11.4)	26 (12.7)
Moderate	4 (33.3)	6 (21.4)	10 (18.9)	17 (24.3)	45 (22.0)
Severe	6 (50.0)	19 (67.9)	37 (69.8)	45 (64.3)	134 (65.4)
Thrombosis	3 (25.0)	4 (14.3)	9 (16.4)	12 (16.7)	33 (15.4)
Delirium	1 (8.3)	5 (17.9)	19 (35.2)	22 (31.0)	45 (21.1)
Requiring oxygen supplementation	12 (100.0)	27 (96.4)	52 (94.5)	72 (97.3)	215 (98.6)
Requiring high flow nasal cannula	0 (0.0)	8 (28.6)	27 (50.9)	23 (32.4)	71 (34.1)
ICU admission	2 (16.7)	8 (28.6)	26 (47.3)	37 (50.0)	78 (35.8)
Invasive mechanical ventilation	2 (16.7)	6 (21.4)	22 (40.0)	35 (47.3)	69 (31.7)
Length of intubation, days	7.0 (3.0-na)	28.0 (11.0-30.0)	14.0 (8.5-23.5)	17.0 (7.0-32.0)	13.0 (7.8-23.0)
Tracheostomy	0 (0.0)	2 (7.4)	9 (16.4)	15 (21.1)	18 (8.3)
Length of ICU stay, days	10.0 (5.0-na)	17.0 (2.0-31.0)	16.0 (9.0-36.8)	22.0 (10.5-35.0)	14.0 (8.0-26.5)
Length of hospital stay, days	5.0 (2.3-8.5)	11.0 (4.3-22.0)	12.0 (6.0-31.0)	15.0 (7.0-39.0)	10.0 (5.0-23.0)

<i>COVID-19 directed Treatment</i>					
None	0 (0.0)	2 (8.0)	6 (11.5)	10 (14.7)	22 (10.3)
(Hydroxy)chloroquine	0 (0.0)	1 (4.0)	1 (1.9)	0 (0.0)	3 (1.4)
Steroids	11 (100.0)	21 (84.0)	44 (84.6)	57 (83.8)	181 (85.0)
Antivirals	1 (9.1)	3 (12.0)	10 (19.2)	12 (17.6)	35 (16.4)
Anti-inflammatory treatment	0 (0.0)	2 (8.0)	6 (11.5)	11 (16.2)	30 (14.1)
Convalescent plasma	0 (0.0)	0 (0.0)	3 (5.8)	1 (1.5)	2 (0.9)
Monoclonal antibodies	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Time interval between discharge and follow-up visit					
3 Months visit, days	91.4 ± 21.6	97.0 ± 12.2	95.3 ± 13.9	95.4 ± 21.5	94.2 ± 26.0
6 Months visit, days	186.8 ± 7.2	183.2 ± 10.3	191.4 ± 18.0	182.4 ± 47.0	184.4 ± 28.1
12 Months visit, days	358.3 ± 19.6	366.6 ± 10.6	365.7 ± 6.6	371.4 ± 22.8	369.3 ± 22.6

Data are presented as n (%), mean ± standard deviation, or, for non-normally distributed variables, as median (interquartile range). Outcomes are stratified divided by the number of symptoms clusters affected (the four symptoms clusters comprise physical, respiratory, cognitive and fatigue symptoms).

^aAdjusted n is presented for variables with a total number of patients less than 408. BMI, body mass index; PCR, Polymerase Chain Reaction, SARS-CoV-2, Severe Acute Respiratory Syndrome coronavirus 2; ICU, Intensive Care Unit; na, not applicable.

Appendix 1

Corona Symptom Checklist

The following complaints may be experienced after COVID-19. Check for each question whether you experienced the complaint at this moment **and** is new since the COVID-19. When you experienced the complaints already before the infection and this did not change, please check “no”. When the complaints *worsened* or is *new* after infection, please check “yes”.

Complaint:	Yes	No
Do you experience a reduced vision?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced hearing?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced taste?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced smell?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience coughing problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience phlegm?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience a reduced voice?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience balance problems or dizziness?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience stool problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience miction problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience fatigue?*	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience dyspnea?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience joint complaints?	<input type="checkbox"/>	<input type="checkbox"/>

Do you experience muscle weakness?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience reduced fitness?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience hair loss?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience skin rash?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience claudication?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience sensory overload?*	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience concentration problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience memory problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience headache?*	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience sleeping problems?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience anxiety/nightmares?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience tingling and or pain in extremities?	<input type="checkbox"/>	<input type="checkbox"/>
Do you experience chest pain?*	<input type="checkbox"/>	<input type="checkbox"/>

*These questions were added from June 2021 onwards